cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Qiagen Nv
9 own
8 watching
Current Price
$41.45
$0.29
(0.7%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
10,361.91M
52-Week High
52-Week High
51.18000
52-Week Low
52-Week Low
34.74000
Average Volume
Average Volume
0.95M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
35.368
iconMarket Capitalization10,361.91M
icon52-Week High51.18000
icon52-Week Low34.74000
iconAverage Volume0.95M
iconDividend Yield--
iconP/E Ratio35.368
What does the Qiagen Nv do?
QIAGEN N.V. provides sample to insight solutions that transform biological materials into valuable molecular insights worldwide. It offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technology solutions. The company provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene- and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. It also offers instrumentation systems for laboratories to perform nucleic acid sample preparation, assay setup, target detection, and interpretation of genomic information. The company's automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories; Modaplex, a multimodal automation system; QIAcube, a sample processing instrument; EZ1 Advanced XL for automated nucleic acid purification; QIAxcel for nucleic acid separation; QIAscout that enables researchers to select and isolate viable single cells; PyroMark, a detection platform that enables real-time analysis and quantification of genetic mutations and DNA methylation patterns; QIAgility, a benchtop instrument; and ESEQuant instruments that enable optical measurement for point of need molecular testing in healthcare and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Read More
News & Events about Qiagen Nv.
Globe Newswire
5 months ago
Venlo, the Netherlands, June 16, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a notice (reiterating its notice to holders dated January 9, 2019) to holders of the following: - 0.500% Senior Unsecured Convertible Notes due 2023 (the "2023 Notes") ...
Zolmax
7 months ago
Sumitomo Mitsui Trust Holdings Inc. increased its position in Qiagen (NYSE:QGEN Get Rating) by 10.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 452,524 shares of the companys stock after buying an ...
Globe Newswire
7 months ago
Launch of cell-free DNA (cfDNA) next-generation sequencing kits to test liquid biopsies // Study to demonstrate QIAGENs expertise in detecting disease-relevant cfDNA mutations // New pan-cancer panels for digital PCR platform QIAcuity to be launched in fall 2023Venlo, the Netherlands, April 14, 2023...
Globe Newswire
8 months ago
SBTi has validated the QIAGEN targets to reach net-zero greenhouse gas (GHG) emissionsVenlo, The Netherlands, March 27, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its emissions reduction targets have been validated by the Science Based ...
Business Wire
8 months ago
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO, an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of the...
Frequently Asked Questions
Frequently Asked Questions
What is Qiagen Nv share price today?
plus_minus_icon
Can Indians buy Qiagen Nv shares?
plus_minus_icon
How can I buy Qiagen Nv shares from India?
plus_minus_icon
Can Fractional shares of Qiagen Nv be purchased?
plus_minus_icon
What are the documents required to start investing in Qiagen Nv stocks?
plus_minus_icon
What is today’s traded volume of Qiagen Nv?
plus_minus_icon
What is today’s market capitalisation of Qiagen Nv?
plus_minus_icon
What is the 52-Week High and Low Range of Qiagen Nv?
plus_minus_icon
What percentage is Qiagen Nv down from its 52-Week High?
plus_minus_icon
What percentage is Qiagen Nv up from its 52-Week Low?
plus_minus_icon
Current Price
$41.45
$0.29
(0.7%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00